{"id":4897,"date":"2014-06-02T15:59:09","date_gmt":"2014-06-02T13:59:09","guid":{"rendered":"https:\/\/www.institut-biotherapies.fr\/?p=4897"},"modified":"2014-06-02T15:59:10","modified_gmt":"2014-06-02T13:59:10","slug":"european-medicines-agency-recommends-first-in-class-medicine-for-treatment-of-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/www.institut-biotherapies.fr\/en\/2014\/06\/02\/european-medicines-agency-recommends-first-in-class-medicine-for-treatment-of-duchenne-muscular-dystrophy\/","title":{"rendered":"European Medicines Agency recommends first-in-class medicine for treatment of Duchenne muscular dystrophy"},"content":{"rendered":"<p>The European Medicines Agency\u2019s Committee for Medicinal Products for Human Use(CHMP) has recommended granting a conditional marketing authorisation for Translarna (ataluren), an orphan-designated medicine for the treatment of Duchenne muscular dystrophy caused by nonsense mutations. Translarna is to be used in patients aged five years and older who are able to walk&#8230;<\/p>\n<p style=\"text-align: center;\"><a href=\"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2014\/05\/news_detail_002110.jsp&amp;mid=WC0b01ac058004d5c1\" target=\"_blank\">Read the press realease on EMA web site\u00a0<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The European Medicines Agency\u2019s Committee for Medicinal Products for Human Use(CHMP) has recommended granting a conditional marketing authorisation for Translarna (ataluren), an orphan-designated medicine for the treatment of Duchenne muscular dystrophy caused by nonsense mutations. Translarna is to be used in patients aged five years and older who are able to walk&#8230; Read the press &hellip; <a href=\"https:\/\/www.institut-biotherapies.fr\/en\/2014\/06\/02\/european-medicines-agency-recommends-first-in-class-medicine-for-treatment-of-duchenne-muscular-dystrophy\/\">[Read more]<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-4897","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/4897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/comments?post=4897"}],"version-history":[{"count":1,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/4897\/revisions"}],"predecessor-version":[{"id":4898,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/4897\/revisions\/4898"}],"wp:attachment":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/media?parent=4897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/categories?post=4897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/tags?post=4897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}